Schedule 13G ownership disclosure
Fate Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 31189P102
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- THE GOLDMAN SACHS GROUP, INC.
Shares: 2,274,020.09 · Class: 2.0%
- GOLDMAN SACHS & CO. LLC
Shares: 2,274,020.09 · Class: 2.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000769993-25-000505
- Form type
- SCHEDULE 13G/A
- Filer
- FATE THERAPEUTICS INC
- CIK
- CIK 1434316
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership